Logo image
Long-term outcome comparison for standard fractionation (>= 59 Gy) versus hyperfractionated (>= 45 Gy) radiotherapy plus concurrent C chemotherapy for limited-stage small-cell lung cancer
Journal article   Open access   Peer reviewed

Long-term outcome comparison for standard fractionation (>= 59 Gy) versus hyperfractionated (>= 45 Gy) radiotherapy plus concurrent C chemotherapy for limited-stage small-cell lung cancer

John M. Watkins, J. Kyle Russo, Nicholas Andresen, Coyt R. Rountree, Amir Zahra, Sarah L. Mott, Daniel J. Herr, Jacy O'Keefe, Bryan G. Allen, Anand K. Sharma, …
Reports of practical oncology and radiotherapy, Vol.25(4), pp.489-493
07/01/2020
DOI: 10.1016/j.rpor.2020.03.017
PMCID: PMC7251533
PMID: 32477014
url
https://pmc.ncbi.nlm.nih.gov/articles/PMC7251533/View
Published (Version of record) Open Access

Abstract

Background: Concurrent chemoradiotherapy (CCRT) is commonly employed in limited-stage small-cell lung cancer (LS-SCLC); however, the optimal radiotherapy regimen is still unknown. This 3-institution analysis compares long-term disease control and survival outcomes for once- (QD) versus twice-daily (BID) radiotherapy at contemporary doses. Methods and Materials: Data were collected for LS-SCLC patients treated with platinum-based CCRT and planned RT doses of >= 5940 cGy at >= 180 cGy QD or >= 4500 cGy at 150 cGy BID. Comparative outcome analyses were performed for treatment groups. Results: From 2005 through 2014, 132 patients met inclusion criteria for analysis (80 QD, 52 BID). Treatment groups were well-balanced, excepting higher rate of advanced mediastinal staging, longer interval from biopsy to treatment initiation, and lower rate of prophylactic cranial irradiation for the QD group, as well as institutional practice variation. At median survivor follow-up of 33.5 months (range, 4.6-105.8), 80 patients experienced disease failure (44 QD, 36 BID), and 106 died (62 QD, 44 BID). No differences in disease control or survival were demonstrated between treatment groups. Conclusion: The present analysis did not detect a difference in disease control or survival outcomes for contemporary dose QD versus BID CCRT in LS-SCLC. (C) 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.
Oncology Life Sciences & Biomedicine Radiology, Nuclear Medicine & Medical Imaging Science & Technology

Details

Metrics

Logo image